SensorStim Neurotechnology
SensorStim Neurotechnology GmbH develops and manufactures ultra-compact and wearable neurostimulation systems designed to help people with paralysis, pain, and spasticity regain mobility. The company specializes in controlled functional electrical stimulation and transcutaneous spinal cord stimulation using miniature wireless sensor technology, including a patented groundbreaking technology for electrical stimulation in water. Their primary product, Stim2Go, is a wearable, app-controlled neurorehabilitation system that uses biofeedback from a built-in sensor to trigger stimulation patterns, supporting patients in movement execution. They also engage in research projects like Mobil4Park for Parkinson's patients and STARS for multiple sclerosis patients, focusing on AI-based gait analysis and adaptive spinal cord stimulation. The company was founded in 2017 as a spin-off from TU Berlin, has a strategic investor in the Pajunk Group, and has seen positive results in clinical evaluations, with participants reporting good acceptance and a desire to use the system.
SensorStim Neurotechnology
SensorStim Neurotechnology GmbH develops and manufactures ultra-compact and wearable neurostimulation systems designed to help people with paralysis, pain, and spasticity regain mobility. The company specializes in controlled functional electrical stimulation and transcutaneous spinal cord stimulation using miniature wireless sensor technology, including a patented groundbreaking technology for electrical stimulation in water. Their primary product, Stim2Go, is a wearable, app-controlled neurorehabilitation system that uses biofeedback from a built-in sensor to trigger stimulation patterns, supporting patients in movement execution. They also engage in research projects like Mobil4Park for Parkinson's patients and STARS for multiple sclerosis patients, focusing on AI-based gait analysis and adaptive spinal cord stimulation. The company was founded in 2017 as a spin-off from TU Berlin, has a strategic investor in the Pajunk Group, and has seen positive results in clinical evaluations, with participants reporting good acceptance and a desire to use the system.